VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 07, 2008) - enGene Inc., a privately held biotechnology company developing an innovative approach for the treatment of diabetes called GEMS™-Insulin, announced today that the board welcomed new member A. Sinclair Dunlop and announced the retirement of John C. Brown and A. Lad Burgin from the board following their significant contribution to enGene.
